NextCure (NXTC) Earnings Analysis

NextCure (NXTC) next reports earnings on 2026-08-06, consensus EPS -1.98 USD. Last quarter (2026-05-07) it missed with EPS -1.87 USD vs -1.81 USD est (-3.3%). It has beaten estimates in 2/7 recent quarters (29%). Trailing P/E -0.23.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NXTC next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-1.98 USD
Revenue estimaten/a

NXTC earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-1.87 USD-1.81 USD-3.3%Miss
2026-03-05-0.81 USD-2.26 USD+64.2%Beat
2025-08-07-11.29 USD-4.62 USD-144.4%Miss
2025-05-01-4.68 USD-4.8 USD+2.5%Beat
2025-03-06-4.92 USD-4.08 USD-20.6%Miss
2024-11-07-4.92 USD-4.2 USD-17.1%Miss
2024-08-01-6.6 USD-4.32 USD-52.8%Miss

Beat rate: 2/7 (29%) over reported quarters with consensus data.

NXTC valuation and analyst view

Trailing P/E-0.23
Trailing EPS-10.43358 USD
Price / book0.86
Dividend yield0.00%
Market cap0.01B
Analyst consensusBuy (11 buy / 1 hold / 1 sell)
Avg price target20 USD

Related research pages

Frequently asked questions

When is NextCure (NXTC)'s next earnings date?

NextCure is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -1.98 USD.

Did NXTC beat earnings last quarter?

In its 2026-05-07 report, NXTC posted EPS of -1.87 USD versus a -1.81 USD estimate — a miss of 3.3%.

What is NXTC's earnings track record?

Over the last 7 reported quarters with consensus data, NXTC beat estimates 2 times (29%).

What is NXTC's current P/E ratio and EPS?

NXTC trades at a trailing P/E of -0.23 on trailing EPS of -10.4335823009309 USD.

What do analysts rate NXTC?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 11 buy, 1 hold, 1 sell, 0 strong sell). Average 12-month price target: 20 USD.